Hemoglobin A1c (HbA1c) Testing Market Report 2026

The hemoglobin a1c (hba1c) testing market size has grown rapidly in recent years. It will grow from $2.02 billion in 2025 to $2.24 billion in 2026 at a compound annual growth rate (CAGR) of 10.5%. The growth in the historic period can be attributed to rising global diabetes prevalence, increased use of long-term glucose monitoring, expansion of diagnostic laboratory infrastructure, growing awareness of diabetes screening, wider adoption of hba1c as diagnostic standard.

The hemoglobin a1c (hba1c) testing market size is expected to see rapid growth in the next few years. It will grow to $3.31 billion in 2030 at a compound annual growth rate (CAGR) of 10.3%. The growth in the forecast period can be attributed to increasing adoption of home-based diabetes monitoring, rising investments in connected diagnostic devices, expansion of preventive healthcare initiatives, growing focus on early diabetes detection, increasing demand for rapid diagnostic solutions. Major trends in the forecast period include increasing adoption of point-of-care hba1c testing devices, rising demand for portable and home-use hba1c analyzers, growing integration of wireless and connected testing solutions, expansion of high-accuracy laboratory-based hba1c technologies, enhanced focus on standardization and diagnostic accuracy.

The increasing prevalence of diabetes is expected to drive the growth of the hemoglobin A1c (HbA1c) testing market in the coming years. Diabetes is a chronic condition in which the body cannot properly regulate blood glucose levels due to insufficient insulin production or insulin resistance. The incidence of diabetes is rising due to poor dietary habits, particularly high consumption of processed foods and sugary drinks, as well as sedentary lifestyles with minimal physical activity. Additionally, aging populations and a family history of diabetes increase the likelihood of developing the condition. HbA1c testing is used to monitor long-term blood glucose control in individuals with diabetes by measuring the average blood sugar levels over the past 2-3 months. For example, in June 2023, data published by The Lancet, a UK-based periodic data publishing organization, projected global diabetes cases to rise from 529 million in 2021 to 1.3 billion by 2050. Therefore, the increasing prevalence of diabetes is fueling demand for HbA1c testing.

Key companies in the HbA1c testing market are focusing on technological innovations in diagnostic testing, such as at-home HbA1c tests, to provide more convenient, accurate, and accessible solutions for early diabetes detection and management. HbA1c home tests are at-home diagnostic kits that allow individuals to measure their average blood sugar levels over the past 2-3 months, supporting ongoing diabetes monitoring and management. For instance, in February 2023, Hurdle Health, a U.S.-based company specializing in innovative healthcare solutions and diagnostic tools for chronic disease management, launched the Hemoglobin A1c (HbA1c) Test. This at-home blood sample test enables adults to screen for and monitor diabetes, enhancing accessibility to diagnostic testing and improving health outcomes through direct-to-consumer solutions.

In January 2024, Roche Holding AG, a Switzerland-based provider of pharmaceuticals and diagnostics, acquired point-of-care (POC) technology from LumiraDx for $350 million. The acquisition aims to expand Roche’s diagnostics portfolio, strengthen capabilities in decentralized healthcare settings, and provide fast, reliable tests such as the CE-marked HbA1c test without requiring specialized storage. LumiraDx, a UK-based POC technology company, offers immunoassay and clinical chemistry tests for HbA1c.

Major companies operating in the hemoglobin a1c (hba1c) testing market are Roche Holding AG, Thermo Fisher Scientific Inc., Abbott Laboratories, Danaher Corporation, Siemens Healthineers, Tosoh Corporation, Hitachi High-Technologies Corporation, Beckman Coulter Inc, Sysmex Corporation, Bio Rad Laboratories Inc, ARKRAY Inc, Randox Laboratories Ltd, Ortho Clinical Diagnostics, Agappe Diagnostics Ltd, SEKISUI Diagnostics LLC, Helena Laboratories, Transasia Bio Medicals Ltd, EKF Diagnostics, Trinity Biotech plc, HemoCue AB, CPC Diagnostics Pvt Ltd, PTS Diagnostics, Menarini Diagnostics srl, Diazyme Laboratories Inc, Osang HealthCare Co Ltd, Eurolyser Diagnostica GmbH, DiaSys Diagnostic Systems GmbH.

North America was the largest region in the hemoglobin A1c (HbA1c) testing market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the hemoglobin a1c (hba1c) testing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the hemoglobin a1c (hba1c) testing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the hemoglobin a1c testing market by increasing costs of imported diagnostic instruments, biosensors, reagents, cartridges, and electronic components used in laboratory and point-of-care testing systems. Healthcare providers and diagnostic laboratories in North America and Europe are most affected due to reliance on imported analyzers and consumables, while Asia-Pacific faces pricing pressure on device manufacturing and exports. These tariffs are raising procurement costs and influencing pricing strategies for testing kits. However, they are also encouraging local reagent production, regional device assembly, and innovation in cost-efficient and compact HbA1c testing platforms.

The hemoglobin a1c (hba1c) testing market research report is one of a series of new reports that provides hemoglobin a1c (hba1c) testing market statistics, including hemoglobin a1c (hba1c) testing industry global market size, regional shares, competitors with a hemoglobin a1c (hba1c) testing market share, detailed hemoglobin a1c (hba1c) testing market segments, market trends and opportunities, and any further data you may need to thrive in the hemoglobin a1c (hba1c) testing industry. This hemoglobin a1c (hba1c) testing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Hemoglobin A1c (HbA1c) testing measures the percentage of hemoglobin bound to glucose, reflecting the average blood glucose levels over the past 2 to 3 months. It is used to monitor long-term glucose control in diabetic patients and to diagnose diabetes and prediabetes.

The primary types of HbA1c testing include laboratory-based testing and point-of-care (PoC) testing. Laboratory-based testing is performed in a laboratory setting, where blood samples are analyzed using advanced equipment. Product types include instruments, reagents, kits, and technologies, which are categorized into immunoassays, chromatography, enzymatic assays, boronate affinity chromatography, high-performance liquid chromatography, and others. End users of these tests include hospitals and clinics, diagnostic laboratories, homecare settings, and other healthcare facilities.

The hemoglobin A1c (HbA1c) testing market consists of revenues earned by entities by providing services such as home monitoring services, remote patient monitoring solutions, specialized HbA1c assay development, telehealth HbA1c monitoring, and personalized treatment management consulting. The market value includes the value of related goods sold by the service provider or included within the service offering. The hemoglobin A1c (HbA1c) testing market also includes sales of diagnostic reagents, test cartridges, automated analyzers, and calibration standards. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.